Ocugen, Inc. (OCGN)

Moving Past Covaxin, Focusing On Gene Therapy and Pipeline Products


Robert LeBoyerMedia Inquiries
Senior Life Sciences Analyst
May 8, 2023
Report ID: 25810
Get Report
Refer to the full report for the price target, fundamental analysis, and rating.

Equity Research provided by Noble Capital Markets is available at no cost to Registered users of Channelchek.

Already Registered? Click the ‘Get Report’ button to login and view the research report.

Not a Member? Click ‘Join’ or ‘Get Report’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

Ticker
OCGN
Current Price
$0.4
Market Cap
$102.6M
Price Target
Refer to Report
Volume
1.1M
52wk Range
$0.39 - $2.11
Related Research Reports
9/14/2023

OCU400 Update Shows Improvement In Three Vision Measures
OCU400 Update Shows Improvement In Three Vision Measures (OCGN)
8/23/2023

2Q23 Reported With New Clinical Trials To Start Before YE23
2Q23 Reported With New Clinical Trials To Start Before YE23 (OCGN)
5/8/2023

Moving Past Covaxin, Focusing On Gene Therapy and Pipeline Products
Moving Past Covaxin, Focusing On Gene Therapy and Pipeline Products (OCGN)
4/17/2023

Positive Preliminary Data Shows Proof-Of-Concept For OCU400
Positive Preliminary Data Shows Proof-Of-Concept For OCU400 (OCGN)

Inbox Intel from Channelchek.

Informed investors make more money. And it’s all about timing. Get it when it happens.

By clicking submit you are agreeing to the Terms of Use and Privacy Policy
© 2018-2023 Noble Financial Group, Inc. All Rights Reserved. Channelchek is provided at no cost to be used for information purposes only and not as investment advisement.